The global pharmaceutical industry experienced a 17% drop in company filings mentions of regenerative medicine in Q2 2023 compared with the previous quarter, with the highest share accounted for by Sarepta Therapeutics with 10% year-on-year decrease, according to GlobalData’s analysis of over 385 pharmaceutical company filings. GlobalData’s Regenerative Medicine in Medical thematic intelligence report provides an overview of the current landscape, including healthcare, technology, regulatory, macroeconomic trends, and key players. Buy the report here.
Notably, regenerative medicine was one of the most frequently referenced themes in Q2 2023, ranking highest in terms of mentions, ahead of metaverse and online travel, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, Sarepta Therapeutics had the greatest increase in references for regenerative medicine in Q2 2023, compared with the previous quarter. GlobalData identified 37 regenerative medicine-related sentences in the company's filings - 2% of all sentences - and a decrease of 10% in Q2 2023 compared with Q2 2022. Gilead Sciences’s mentions of regenerative medicine rose by 17% to 27 and Bristol-Myers Squibb’s by 550% to 26 and Takeda Pharmaceutical’s by 70% to 17 and Vertex Pharmaceuticals’s by 36% to 15.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for regenerative medicine in Q2 2023 was 100.
For further understanding of GlobalData's Regenerative Medicine in Medical - Thematic Research buy the report here.